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ABSTRACT
Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leading 
to increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3% to 38% for 
major depression and 1.5-52% for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so that 
the quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of both 
very much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selection 
of components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whether 
clinical, psychological, spiritual, or social.
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INTRODUCTION
“Every man has his secret sorrows which the world knows not; and 
oftentimes we call a man cold when he is only sad.” Depression often 
called the common cold of psychiatry is very common in palliative 
care. Depression adds to the physical consequence of advanced 
diseases. Pain, fatigue, and disability usually associate with depression. 
Evidence says depressed patients have very poor prognosis and 
incidence of higher mortality in a range of physical illness. Exposure 
to chronic psychological stressors may lead to the development of 
either depression or anxiety disorders or both [1]. Terminal illness 
is accompanied by normal fear and distress making a diagnosis of 
depression, a hectic task. Furthermore, somatic symptoms of the 
patients may be due to depression, advanced disease or medical 
treatment. Cancer accounts for about 14% of death worldwide with 
numbers increasing up to 25% in western population. The diagnosis of 
cancer is usually perceived as death sentence by many creating mental 
distress and feeling of being tortured by nature. Depression is a well-
recognized risk factor for shortened life span from cancer. Hence, the 
challenge of holistic care has spawned the birth of a new discipline in 
the field of medicine called the psycho - oncology drawing practitioners 
from psychiatry, psychology, oncology, social work, and other relevant 
medical fields to provide great care to cancer patients.
Depression and its prevalence
Depression is among the main causes of disability in the world leading to 
increased suffering and mortality. The United States comorbidity survey 
showed a lifetime prevalence of 16% [2]. When comorbid with medical 
illness prevalence ranges from 20% to 30% in hospitalized patients [3], 
with the highest rates noted with endocrine disorders such as Cushing’s 
disease and lowest rate noted with end-stage renal disease.
Prevalence of depression in cancer patients
As per research surveys over the years, prevalence among cancer 
patients varies widely from 3% to 38% for major depression and 
1.5-52% for depression spectrum syndromes [4]. The prevalence rates 
reported varies due to the varying conceptualization of depression, 
difference in diagnostic criteria, methodological approaches to 
measure depression and also difference in the population studied. The 
variation in prevalence among different types of cancer patients can be 
attributed to the pathophysiologic effect of cancer, treatment effects 
or other unidentifiable factors. Nonetheless, cancer exclusive of the 
site is associated with depression in rates higher compared to normal 
population. Cancer types in association with depression include brain 
(41-93%) [5,6], pancreas (up to 50%) [7], head and neck (42%) [8], 
breast (4.5-38%) [9,10], lung (11%) [11,27], and gynecological 
(23%) [12]. High prevalence is associated with stomach, pancreas, 
breast, and head and neck cancers [13] with lower rates associated 
with colon cancers (13%)and lymphomas (8%) [14]. Sneed et al., [15]
found no gender difference in depression in male and female cancer 
patients; however, women adjusted more positively than men.
DEPRESSION BY CANCER TYPE
Depression in breast cancer
Breast cancer is the most studies cancer type in terms of psychological 
stress. The prevalence of depression ranges from 4.5% to 37%. Studies 
have assessed the rates of major depression as well duration of depression 
in breast cancer patients. Morris et al. [16] studied 160 women awaiting 
breast surgery found 22 % of patients who had mastectomy for malignant 
disease had depression for the next 2 years compared to 8% in those 
with benign disease, similarly Kissane et al. [17] Studied 303 early stage 
and 200 metastatic cancer patients and found prevalence rates of 6.5% 
and 9.6% among early and malignant groups, respectively. A 5 year 
observational cohort study of 222 early cancer patients [18] revealed 
prevalence rates of depression to be 33% at diagnosis of cancer, 15% 
after 1 year and 45% after recurrence of breast cancer was diagnosed. 
Independent risk factors for the development of depression among breast 
cancer patients includes younger age, social status, ethnicity, psychiatric 
history, comorbidity, alcohol, smoking, and body mass index.
Depression in gynecological cancers
A systemic review of 18 studies of psychological distress in ovarian 
cancer patients by Arden - Close et al. [19] found strong evidence 
for a relationship of younger age, increased physical symptoms, 
more advanced disease and short time since diagnosis of depression. 
Gonsalves et al. [20] noted that persistence clinical depression was 
not prevalent (6%) and prevalence was highest at the beginning of 
treatment. Evans et al. [11] reported 23% prevalence of depression 
among ovarian cancer patients.
Depression in head and neck cancers
Head and neck cancers cater high risk of morbidity and mortality with the 
disease per se and treatment factors substantially contributing to disability 
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and loss of vital functions such as communicating, breathing and eating. 
A systematic of review of 52 studies found the association of depression 
with oropharyngeal cancers throughout the trajectory of illness. 
Depression rates were highest (11-45%) at the time of diagnosis, during 
treatment and 6 months follow up. The levels came down (9-27%) 3 years 
after diagnosis [21]. Hammerlid et al. [22] studying 357 patients found 
that those patients having a higher level of mental disability and stress had 
very low-performance status and more advanced disease.
Depression in lung cancer
Lung cancer is usually associated with higher levels of distress when 
compared to other tumor sites. In a study of depression in 129 patients 
lung cancer before and after diagnosis Montazeri et al. [12] found 
12% of patients had depression at the time of presentation and 10% 
at follow-up. Hopwood and Stephens [10] followed 987 lung cancer 
patients and found depression was more prevalent in patients with 
small cell lung cancer than non - small cell cancer.
Depression in brain tumors
Psychiatry problems in brain tumors can be mainly due to the disease 
process itself as well as by treatment including chemotherapy, radiation, 
and corticosteroids. Arnold et al. [6] found 41% of 363 brain tumor 
patients had depressive symptoms, as assessed by brief patient health 
questionnaire. Litofsky et al. [5] found 93% of 598 high-grade Glioma 
patients had depression in the early post-operative period compared to 
15% recognized by physicians thereby highlighting the underdiagnosis 
of depression in this population. Depression, emotional distress, and 
fatigue are interrelated in brain tumor patients, but still depression 
remains important and is an independent predictor of quality of life, 
emphasizing in the importance of diagnosing it and treatment.
Depression in advanced cancer and palliative care
Depression very common among patients with advanced cancer [23], 
yet it remains underdiagnosed and undertreated [24]. Considerable 
barriers are faced by health-care professionals in this area. One of 
them is the common misconception that it is normal for patients 
with advanced cancer to be sad. Despite such barriers, we must not 
ignore the fact that depression is an independent predictor of poor 
survival in advanced cancer. Furthermore, it reduces the quality of 
life and prolongs hospitalization. Most importantly, depression in 
advanced cancer is treatable, and validated assessment tools have been 
developed to facilitate diagnosis. Due to variation in diagnostic criteria, 
prevalence estimates vary widely from 5% to 26% for major depression 
and from 7% to 26% for minor depression in those with advanced 
cancer [6]. The highest prevalence rates of depression have been 
observed in patients with cancers of the pancreas, head and neck, and 
breast. Brintzenhofe-Szoc et al. [13] conducted a large cross-sectional 
study in- and out-patient setting to determine the cancer specific 
prevalence of both pure depression and mixed anxiety/depression. 
The highest prevalence of pure depression was seen in patients with 
pancreatic cancer, whereas the highest prevalence of mixed anxiety/
depression was observed in those with cancer of the stomach. Risk 
factors for developing major depression in advanced cancer include 
history of depression, pain, poor functional status, limited social 
network, and younger age. Psychological concomitants promoting 
depression include the emotional impact of the advanced disease 
status, side effects of medications, the progression of cancer with its 
severe disability, and cerebral dysfunction. Depression in advanced 
cancer not only reduces the quality of life but also decreases survival 
time, reduces treatment compliance and prolongs hospital admission 
with the additional psychological burden on caregivers and family 
members. It increases the desire to hasten death in terminally ill cancer 
patients. Recent studies have suggested that depression is associated 
with interest in physician-assisted suicide. There is also instability of 
this interest. A request for assisted suicide, when confronted by the 
patient, the possibility of depression should always be considered. 
There are no universally accepted criteria for diagnosing depression 
in the terminally ill patient. As neurovegetative features are associated 
with advanced cancer, difficulties arise in distinguishing whether the 
somatic symptoms identified in the DSM-IV criteria are attributable to 
depression or to cancer [26]. Disclosure of emotional concerns with 
medical professionals is one of the biggest concerns among patients 
resulting in depression frequently undetected in advanced cancer. 
These barriers in diagnosis have led to the development of assessment 
tools. Such screening instruments are not diagnostic and only serve to 
identify those patients with symptoms suggestive of depression. After 
identification of patients by screening, further assessment is warranted 
before treatment is commenced. The hospital anxiety and depression 
scale (HADS) devised by Zigmond and Snaith [27] remains one of the 
most widely used tools. The HADS is a self-reported questionnaire with 
14 items and was originally developed as a screening tool for medical 
patients. Although the HADS appears to perform significantly well in 
those patients on active anti-cancer treatment, it performs less well 
in those with progressive disease. So when used alone as a screening 
tool it has very limited sensitivity and specificity. The Edinburgh 
depression scale (EDS) originally developed to screen for postnatal 
depression in the community, has shown much promise [28]. One study 
of palliative care patients using the EDS found that a cut-off threshold 
of 13 had a sensitivity of 0.79, a specificity of 0.81 and a positive 
predictive value of 0.53 using ICD-10 criteria [29] for depression in 
comparison with a sensitivity of 0.77 and a specificity of 0.85 for the 
HAD scale [30]. More recently, a brief EDS (BEDS) has been designed, 
which more is discriminating for depression in patients with advanced 
cancer. The BEDS has a sensitivity of 0.72, a specificity of 0.83 and a 
positive predictive value of 0.65 [31]. This tool is now widely used in 
the palliative care setting for depression screening. Evidence says 
that depression is not only underdiagnosed but also undertreated in 
advanced cancer. The single most important barrier to treatment is the 
common misconception that it is normal for patients with advanced 
cancer to be sad. Pre-conceived ideas that psychological treatment is 
better than pharmacological treatment, and attitudes of therapeutic 
nihilism, that is, nothing works at this stage are some of other barriers 
for treatment of depression in advanced cancer. In those situations 
where antidepressant medication is commenced, it is frequently given 
at inadequate doses or too late for the therapeutic effect of the drug to 
take place. One survey conducted in the UK palliative care units found 
that 76% of antidepressants were started in the past 2 weeks of life in 
patients with advanced cancer [32].
MANAGEMENT
Rationale
The need of the hour is to effectively treat depression in cancer 
patients and hence that the QOL can be improved and thereby patient 
survival. Both psychological and pharmacological interventions and 
the combination of both very much effective in treating depression in 
cancer patients. Two main class of drugs used in treating depression 
are Tricyclic anti-depressants (TCA) and serotonin reuptake inhibitors 
(SSRI) with later being the first-line agent and the former being the 
second-line agent [33]. The exact mechanism of these drugs has not been 
established, but they bring adaptive changes in the brain and overtime 
increase the levels of 5HT levels thereby increasing mood [34]. The first 
AD’s were available 50 years ago, they include TCA’s such as amitriptyline 
and imipramine and monoamine oxidase inhibitors (MAO’S) such as 
phenelzine. Development of newer AD’s over the past two decades has 
modified the treatment approach to depression. They include SSRIs and 
SNRIs. Therefore, a good knowledge of the profile of drugs and their side 
effects are extremely important. Cancer patients usually complaint of 
constipation, urinary retention, stomatitis, seizures, or cardiac problems 
such as arrhythmias and orthostatic hypotension which warrants careful 
selection of AD’s. The main characteristics of AD’s are summarized in 
(Table 1). MAOIs are generally contraindicated and not considered 
safe in cancer patients, because of the high rates of side effects. MAOIs 
can interact with opioids, sympathomimetics, and procarbazine and 
can lead to hypertensive crises. In addition, MAOIs interact with some 
anesthetic drugs when cancer patients undergo surgery. The use of TCAs 
has been gradually decreasing, because their anti-muscarinic properties 
may be extremely dangerous for cancer patients (e.g., dry mouth in 
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patients with mucositis due to chemotherapy, reduction of bowel 
peristalsis in patients receiving opioids for pain, confusional states, and 
delirium in debilitated cancer patients). In contrast, the use of SSRIs and 
SNRIs has increased because of higher safety profile [35,36], although 
cardiovascular adverse effects, abnormal bleeding, hyponatremia, 
seizures, and agranulocytosis should be kept in mind while treating 
cancer patients [37]. Psychostimulants (e.g., methylphenidate, pemoline, 
d-amphetamine)are useful in the treatment of depression in cancer, in 
terminally ill patients, because of their rapid onset of action and effect 
concentration and attention problems and also on fatigue [38]. ADs 
usually start working within 2 weeks, but other medications in cancer 
patients may have an impact on antidepressant metabolisms, such as 
steroids, anti-emetics, and narcotics. Usually, patients are started off on 
low dosages of ADs to check for any side effects such as rash, or adverse 
drug-drug interactions, and then escalated to full dosage. The full benefit 
is seen by patients in 4-6 weeks or maybe even longer.
Neutropenia is a one among the possible complication of the use of 
TCAs [39] mianserin [40] and mirtazapine [41] with data also for 
fluoxetine, trazodone, nefazodone, and sertraline [42]. Examination of 
white cell count is extremely important in cancer patients receiving 
chemotherapy. Patients with lung cancer often have dyspnea, anxiety, 
pain and, in about 25% of the cases, clinically significant depressive 
states [42]. Whereas, the use of ADs is not generally contraindicated, 
benzodiazepines should be generally avoided. Although they may 
provide short-term relief of anxiety, they, in fact, exacerbate breathing 
difficulties and, in combination with opioids, causing detrimental 
effect on pulmonary function. Bowel obstruction is very common in 
patients with ovarian cancer. Anti-cholinergic should be avoided in 
these patients as it reduces bowel movements ADs should also be 
carefully when used in cancer patients receiving opioids for pain in 
view of their own peristalsis. Since these drugs are metabolized by 
the liver, they should be carefully used in patients with compromised 
liver function as well in those patients with liver tumors receiving 
treatment. Hence, baseline and periodic liver function tests are 
warranted. Among ADs, nefazodone may cause fatal hepatotoxicity 
and should not be used in patients with liver dysfunction. It is 
necessary to avoid anticholinergic medications, such as the TCAs, in 
patients with delirium [43].
Some guidelines for the use of ADs in cancer patients
•	 Treatment	initiation	at	low	doses	and	then	followed	dose	titration	
to achieve an optimum response to avoid side effects.
•	 Inform	patients	of	latency	period	and	possible	side	effects	to	avoid	
premature drop-out, inpatients receiving other medications.
•	 Treat	the	patient	for	4-6	months	to	avoid	relapses	or	new	episodes	
of depression after remission.
•	 Regular	monitoring	of	the	physical	variables	and	other	medications	
used for cancer (for example, steroids, antiemetic’s, antibiotics, 
antiestrogen, and chemotherapy agents).
•	 By	tapering	the	dose	by	50%	over	a	couple	of	weeks	to	reduce	the	
risk of withdrawal drugs should be discontinued.
•	 Education	and	proper	 reassurance	of	 the	patients	are	extremely	
important in oncology settings.
Psychotherapy for depression in cancer and palliative care
Evidence-based medicine warrants the use of effective interventions 
ahead of non-efficacious treatment. Jacobsen and Jim suggest that 
psychosocial cancer care that is ineffective is worse than not caring 
at all. It is highly pertinent to assess intervention’s impact rather than 
relying on good intentions alone. We begin with individually-focused 
therapies for patients with early stage cancer, move to systemic 
therapies (couple, group, and family) that bridge across all stages of 
cancer and then psychotherapy for advanced cancer, including patients 
receiving palliative care.
PSYCHOTHERAPIES IN EARLY STAGE CANCER
Individually-focused psychotherapies
Issues and symptoms
As depression phenotype is heterogeneous in cancer it is of high 
importance to formulate the case with differential diagnosis before 
the start of psychotherapy. Depression must be viewed within the 
bio-psychosocial context of the person, rather than as an isolated 
symptom cluster. The differential diagnosis for major depression 
includes mood disorder due to a medical condition, substance induced 
mood disorder, dementia, delirium, and bipolar disorder. In these 
cases, the primary treatment should be underlying condition and not 
necessarily on psychotherapy. Even though it requires a temporal 
association between the onset and course of the medical condition and 
depression, psychiatric symptoms of a medical illness may antedate its 
clinical recognition. Correction of the medical illness may not eliminate 
the depressive symptoms since depression is often multicentered. 
Comorbid substance abuse may also benefit from specific drug 
treatments, inpatient detoxification, or psychotherapies [44].
Cognitive therapy (CT)
CT or cognitive-behavioral therapy (CBT) is based on the hypothesis 
that it is not the situation that causes an emotional reaction but rather 
how a person perceives that situation [45]. Triggering a situation 
Table 1: Characteristics of anti‑depressants
Class of drugs Disadvantages Advantages
A. TCA’s e.g., Imipramine, desipramine, 
clomipramine and amitriptyline
Constipation, dry mouth, drowsiness, postural 
hypotension reflex tachycardia
Action on pain
B. SSRI’s e.g., fluvoxamine, paroxetine, sertraline, 
citalopram, escitalopram
Sexual dysfunction, gastrointestinal side 
effects
Action on sleep
C. SNRI’s e.g., reboxetine Decreased blood pressure
Dizziness, dry mouth, urinary retention
Some more sedative
D. SSNRI’s e.g., Venlafaxine, desvenlafaxine, 
duloxetine, milnacipram
Hypotension Improved drive and cognitive functions
E. Selective dopamine and noradrenaline reuptake 
inhibitors e.g., Bupropion
Anxiety, psychomotor activation Decrease fatigue, increased attention
F.  Noradrenergic and specific serotonergic reuptake 
inhibitors e.g., mirtazapine
Drowsiness Drowsiness (helpful in insomnia)
G. Serotonin antagonists and reuptake inhibitors 
e.g., trazodone, nefazodone
NIL Rapid effect
H. Psychostimulants dextro-amphetamine, 
methylphenidate, modafinil
Restlessness, agitation, insomnia, nightmares, 
anorexia, arrhythmia, tachycardia, tolerance, 
dependence, seizures
Action on pain
TCA: Tricyclic anti-depressants, SSRI: Serotonin reuptake inhibitors, SNRI: Serotonin norepinephrine reuptake inhibitors, SSNRI: Selective serotonin norepinephrine 
reuptake inhibitors
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leads to an “automatic thought” which then generates a response 
that can be emotional (e.g., worry), behavioral (e.g., withdrawal), or 
physiological (e.g., gastrointestinal discomfort). Important component 
of CT is reframing of dysfunctional automatic thoughts. The main aim 
is to moderate the intensity of cognitive thinking biases by engaging 
the patient in a consideration of more reasonable alternatives. 
Evidence supporting the efficacy of CBT for depression can be 
found in meta-analyses of multiple randomized controlled trials in 
cancer survivors [46]. A newer paradigm recommends the use of a 
psychotherapy intervention to prevent distress among patients at high 
risk for depression. Pitceathly et al. [47]. Demonstrated that a short 
course of CBT intervention (three sessions), administered by trained 
nurses, significantly reduced the rate of depression in high-risk patients 
but not depressed at baseline. The first session was conducted face to 
face, but subsequent sessions were conducted by phone. Significant 
effects were noted up to 6 months after the intervention. Team of 
well -trained nurse therapists is another welcome improvement to 
allow more patients access to depression treatment.
Problem-solving therapy
It is based on the hypothesis that more efficient problem solving or 
improved coping results in less psychological distress. The standard 
90 minutes*10 sessions trains patients to define the problem, evaluate 
possible options, brainstorm potential solutions, monitor success, and 
refine them. A family member can be designated the team leader, as 
cancer affects whole family and people collaborate in solving it [48]. In a 
randomized controlled study, problem solving was effective in reducing 
depressive symptoms (p<0.05) versus a waiting list control, a benefit 
that was still robust at 1 year [49].
Psycho-educational interventions
Psycho-educational interventions orients patients to novel oncology 
situations by providing verbal, visual, and written help to patients. 
Acquisition of new knowledge is essential to help patients learn new 
medical systems. Devine and Westlake’s meta-analysis of 116 psycho-
educational studies [50] reported a moderate effect size (d=0.54, 
95% CI=0.43-0.65) for the amelioration of depression, and a positive 
result was found in a systematic qualitative analysis of 63% of studies 
reviewed [50]. The fact that better orientation and support in unfamiliar 
medical situations can reduce demoralization and helplessness and can 
shape better expectations.
Relaxation therapies
It is one among the most widely used psychosocial services offered to 
cancer patients and are particularly useful for managing “here and now” 
behaviors or distress associated with cancer treatments. Luebbert’s 
meta-analysis [51] estimated a moderate effect size of relaxation on 
depression (d=0.54, 95% CI=0.30-0.78). Jacobsen et al. [52] developed 
a self-administered stress management intervention for chemotherapy 
self-administered, using print, and audio instructions. Using three 
techniques (paced abdominal breathing, progressive muscle relaxation 
with guided imagery, and coping self-statements), depression, and 
anxiety symptoms were significantly less than in the control group after 
two, three, and four cycles of chemotherapy.
Interpersonal therapy (IPT)
IPT focus on interpersonal conflicts, life transitions, grief, losses, and 
social isolation, all of which are pertinent contextual issues for the 
depressed cancer patient. In a meta-analysis, IPT was superior to 
placebo in 8 out of 13 studies [53], but unlike CBT, it had no documented 
additive effect when given together with an antidepressant [53]. 
Specific psycho-oncology data are lacking at this time.
Systemic psychotherapies
Issues and settings
The distress of cancer reverberates through couples, families, and 
communities. Higher rates of depression have been observed in the 
spouses of patients with prostate cancer [54] and with non-gender 
based metastatic cancers [55]. Hence, there is a need for models 
of psychotherapy within oncology that target couples and families, 
especially in the setting of advanced disease. For isolated people, 
a group approach can be crucial as a primary means to foster social 
support.
Couple therapy
Main targets of couple therapy are Relationship enhancement and 
protection against relational distress. Fostering open communication 
promotes mastery, while using the relationship as a key source of 
mutual support [56]. In the breast cancer setting, a randomized 
controlled trial of an active coping intervention for couples relative 
to usual care showed a reduction in women’s depressive symptoms 
up to 6 months post-treatment [57]. Couple therapy in prostate 
cancer is illustrated by the FOCUS intervention, which targets family 
involvement, optimistic attitude, coping effectiveness, uncertainty 
reduction and symptom management couple therapy in the setting of 
advanced cancer shifts the emphasis to anticipated loss, caregiving, 
and existential concerns [58]. Emotion-focused couple therapy 
addresses threats to emotional engagement by recognizing distancing 
interactions and promoting closeness and thereby reducing depression. 
Effective mutual support results when couples are securely attached to 
each other. Couple therapy that identifies existential fears and supports 
intimacy in the face of death to protect against demoralization and 
depression.
Group therapy
Supportive-expressive group therapy (SEGT) [59] is efficacious in 
relieving distress, and successfully helps in the treatment of depression, 
as well as preventing its onset in the advanced cancer setting. In 
cognitive-existential group therapy (CEGT), therapists aim to promote 
a supportive environment, facilitate grief work over the multiple 
losses, alter maladaptive cognitive patterns, improve problem solving 
and coping skills, foster a sense of mastery and encourage review of 
lifestyle priorities for the future [60]. Clear focus is emphasized on 
(a) the cancer journey, (b) its existential challenges, (c) coping with 
anti-cancer treatments, (d) supporting adherence to the medical 
regimen, (e) cognitive strategies to counter fear of recurrence and living 
with uncertainty, (f) optimizing relationships with physicians, partners, 
families and friends, and (g) meaning-making through recognition of 
what is fulfilling, creative and purposeful in life. The goals of SEGT are to 
build bonds, express emotions, detoxify death, redefine life’s priorities, 
fortify families and friends, enhance doctor-patient relationships and 
improve coping. With such extraordinary influence on the cancer 
patient’s life, SEGT actually protects cancer patients from developing 
new cases of clinical depression compared to those receiving usual 
cancer care [61].
Family therapy
Family-centered care harness areas of competence, affirm skills 
and promote hope and reintegration when cancer experiences can 
contribute to hopeless feeling among family members. There is a 
correlation between poor family support and recurrence of depression 
resulting in devastating complications [62]. In a randomized controlled 
trial targeting ‘at risk’ families, family therapy that was designed to 
provide effective communication, enhanced cohesion and was found 
to reduce depression and mourning from family loss due to cancer. In 
general, mild family dysfunction needs four to six sessions in comparison 
to 10-12 sessions for families with pronounced dysfunction. Circular 
questions to unravel family dynamics and offering regular summaries 
to help families integrate [63]. Couple and group models are important 
in early stage while family therapy comes to play mainly with advanced 
cancers.
PSYCHOTHERAPIES IN ADVANCED CANCER AND PALLIATIVE CARE
The inevitable challenge in individuals with advanced disease is the 
psychological well-being, because of the extreme stress and burden 
that comes with it which includes physical suffering and disability, 
the threat of impending doom, alterations of support and personal 
relationships, the challenge of making correct treatment decisions that 
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have life and death implications. Early interventions to treat depressive 
symptoms may help to protect or improve emotional well-being and 
quality of life. Unfortunately, however, the majority of patients at this 
stage of disease are not referred for psychosocial or psychiatric care 
and most of those referred do not receive adequate treatment for 
depression [64]. Although routine distress screening is now regarded 
as a standard in cancer care at all stages of the disease, its benefit is 
always limited due to failure of treatment centers to provide effective 
interventions that follow screening. Therefore an integrated approach 
is needed, which includes symptom control, the social environment 
and the psychological disturbance itself. Psychological treatments for 
depression are preferred when compared to pharmacological care 
and the type of psychotherapy often becomes most appropriate as 
the disease progresses. Individual sessions permit the therapy to be 
flexibly tailored to individual needs and also the timing of the sessions 
can be easily adjusted to take into account other clinic appointments, 
investigations and treatments, and the fluctuating trajectory in health 
status at this stage of disease [65]. Psychotherapy should be advocated 
before debilitating physical symptoms and also before impairment 
in cognition limits the capacity for self-reflection. Models of therapy 
include logo-therapy, existential psychotherapy, grief therapy, life 
review, life narrative, and IPT. The investigational research carried out 
so far to investigate the effectiveness of individual psychotherapies 
in terminally ill patients so far has been limited by the absence of 
appropriate inclusion criteria for the severity of depression and 
inadequate randomization [66]. Several psychotherapy interventions 
are currently being investigated to determine their effectiveness. 
These treatments can be broadly categorized into those that promote 
active coping strategies and those that emphasize the communication 
and understanding of emotional experience and the joint creation of 
meaning, usually described as supportive-expressive therapies.
CONCLUSION
Depression is very common in cancer patients. It results in significant 
morbidity and mortality. Although the prevalence of depression varies 
ranging between 1.5% and 52%, there should be no doubt that cancer 
is associated with a high degree of depression. There is much to do to 
enhance the quality of life of patients with cancer and prevent the onset 
of depression. Further research evidence is needed on the efficacy, 
effectiveness and safety of ADs in the different settings of oncology 
(inpatient units, outpatient clinics and palliative care units) and types 
of cancer. More information is needed about the interactions between 
ADs and the variety of drugs, especially chemotherapeutic agents, 
cancer patients receive. Depression increases suffering in the oncology 
setting. A broad range of therapies now exist and the art of such therapy 
is the strategic selection of components from several models to best 
respond to the needs of the individual patient and his/her family in 
the specific circumstances, whether clinical, psychological, spiritual, or 
social. Although we have pragmatically placed more emphasis on CBT in 
early cancer and supportive- expressive therapies in advanced cancer, 
a wise therapist selects whatever model offers most to the needs of the 
patient at that time. Existential, spiritual, and meaning-based themes 
are commonly met and dealt with in the early stage patient with cancer. 
Furthermore, many of these therapies are appropriately combined with 
psychotropic medication.
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